Fate Therapeutics, Inc.

FATE Real Time Price USD
N/A
N/A
N/A
...
...
Overview
Financials
Forecast
Insiders
Institutions
Government
Ownership
News

Chart provided by TradingView

Income
Balance Sheet
Cash Flow
Revenue Breakdown
Congress Trading

Recent trades of FATE by members of U.S. Congress

Politician Type Traded
Daniel S. Goldman House / D Sale $1,001 - $15,000 Jan 31, 2023
FATE Stock Insider Trading Activity Follow @QuiverQuant for major insider updates
Closing Price
Purchase
Sale
Name
Type
Shares
Price
Shares Held
Date
Reported
FATE Stock Institutional Owners
Investor
Shares
Change in Shares
Market Value
Date
Reported
FATE Derivatives Institutional Owners
Investor
Type
Shares
Change in Shares
Market Value
Date
Reported
Whale Activity

Recently reported changes in FATE holdings by institutional investors

Insider Trading

Quarterly net insider trading by FATE's directors and management

* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.

About

Backtest Start Date
CAGR (Total)
Return (30d)
Return (1Y)
View Strategy Copytrade Strategy
  • 1M
  • 3M
  • 6M
  • YTD
  • 1Y
  • 2Y
  • 5Y
  • MAX

About

Backtest Start Date

Key Metrics

Return (1d)

Return (30d)

Return (1Y)

CAGR (Total)

Max Drawdown

Beta

Alpha

Sharpe Ratio

Win Rate

Average Win

Average Loss

Annual Volatility

Annual Std Dev

Information Ratio

Treynor Ratio

Total Trades

Show More
Metrics Definitions
  • Alpha

    Measures a portfolio's risk-adjusted performance against that of its benchmark

    Learn More
  • Annual Standard Deviation

    Measures how much the portfolio's total return varies from its mean or average.

    Learn More
  • Annual Volatility

    A statistical measure of the dispersion of returns for the portfolio.

    Learn More
  • Average Win

    The average return (%) for trades that resulted in a positive return.

  • Average Loss

    The average return (%) for trades that resulted in a negative return.

  • Beta

    A measure of the volatility of the portfolio compared to the market as a whole.

    Learn More
  • CAGR

    CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.

    Learn More
  • Information Ratio

    A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.

    Learn More
  • Max Drawdown

    the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.

    Learn More
  • Sharpe Ratio

    The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.

    Learn More
  • Total Trades

    The total number of trades made by this strategy.

  • Treynor Ratio

    Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.

    Learn More
  • Win Rate

    The percentage of total trades that resulted in a positive return.

Subscribe to Quiver Premium for insider trading alerts

Be the first to see our newest insights and key updates across all datasets.

See Pricing
schema-2
Corporate Lobbying

Government lobbying spending instances

  • $20,000 Apr 11, 2012 Issue: None
  • $20,000 Jan 10, 2012 Issue: Medical/Disease Research/Clinical Labs Budget/Appropriations Defense
  • $20,000 Oct 12, 2011 Issue: Medical/Disease Research/Clinical Labs Budget/Appropriations Defense
  • $20,000 Jul 18, 2011 Issue: Defense Budget/Appropriations Medical/Disease Research/Clinical Labs
  • $20,000 Apr 10, 2011 Issue: Medical/Disease Research/Clinical Labs Budget/Appropriations Defense
  • $20,000 Jan 12, 2011 Issue: Medical/Disease Research/Clinical Labs Defense Budget/Appropriations
  • $25,000 Oct 14, 2010 Issue: Medical/Disease Research/Clinical Labs Budget/Appropriations Defense
  • $25,000 Jul 17, 2010 Issue: Budget/Appropriations Defense Medical/Disease Research/Clinical Labs
  • $20,000 Apr 18, 2010 Issue: Medical/Disease Research/Clinical Labs Budget/Appropriations Defense
  • $20,000 Jan 14, 2010 Issue: Medical/Disease Research/Clinical Labs Budget/Appropriations Defense
  • $20,000 Oct 17, 2009 Issue: Medical/Disease Research/Clinical Labs Budget/Appropriations Veterans Defense
  • $20,000 Jul 18, 2009 Issue: Medical/Disease Research/Clinical Labs Budget/Appropriations Defense Veterans
  • $20,000 Apr 14, 2009 Issue: Medical/Disease Research/Clinical Labs Budget/Appropriations
Corporate Lobbying

FATE Estimated quarterly lobbying spending

Quiver Logo

No Corporate Lobbying data for this ticker

Corporate Lobbying Dashboard
Revenue Breakdown

FATE Revenue by Segment or Geography

By Segment
By Geography
Quiver Logo

No Revenue by Segment data for this ticker

Revenue Breakdown Dashboard
Quiver Logo

No Revenue by Geography data for this ticker

Revenue Breakdown Dashboard
FATE Income Statement
FATE Balance Sheet
FATE Cash Flow
U.S. Patents

New FATE patent grants

  • Patent Title: Immunotherapies using enhanced ipsc derived effector cells Oct. 07, 2025
  • Patent Title: Compositions and methods for immune cell modulation in adoptive immunotherapies Sep. 23, 2025
  • Patent Title: Cell culture platform for single cell sorting and enhanced reprogramming of ipscs Sep. 16, 2025
  • Patent Title: Methods and compositions for inducing hematopoietic cell differentiation Sep. 09, 2025
  • Patent Title: Enhanced immune effector cells and use thereof Aug. 26, 2025
  • Patent Title: Methods and compositions for inducing hematopoietic cell differentiation Aug. 12, 2025
  • Patent Title: Platform for the induction and maintenance of ground state pluripotency Jul. 08, 2025
  • Patent Title: Compositions and methods for immune cell modulation in adoptive immunotherapies Apr. 22, 2025
  • Patent Title: Combining ipsc derived effector cell types for immunotherapy use Apr. 15, 2025
  • Patent Title: Minimal volume reprogramming of mononuclear cells Apr. 01, 2025
  • Patent Title: Cellular reprogramming using temporal and transient plasmid vector expression system Mar. 11, 2025
  • Patent Title: Cells having solid tumor targeting backbone and use thereof Jan. 21, 2025
  • Patent Title: Enhanced immune effector cells and use thereof Dec. 24, 2024
  • Patent Title: Chimeric antigen receptor for tumor targeting Oct. 22, 2024
  • Patent Title: Compositions and methods for immune cell modulation in adoptive immunotherapies Jul. 16, 2024
  • Patent Title: Vial rack Sep. 05, 2023
  • Patent Title: Methods and compositions for inducing hematopoietic cell differentiation Apr. 25, 2023
  • Patent Title: Platform for the induction and maintenance of ground state pluripotency Sep. 13, 2022
  • Patent Title: Compositions and methods for immune cell modulation in adoptive immunotherapies Aug. 16, 2022
  • Patent Title: Enhanced immune effector cells and use thereof Jun. 21, 2022
  • Patent Title: Genomic engineering of pluripotent cells Jun. 07, 2022
  • Patent Title: Reprogramming methods and cell culture platforms Mar. 08, 2022
  • Patent Title: Methods and compositions for inducing hematopoietic cell differentiation Nov. 02, 2021
  • Patent Title: Methods and compositions for inducing hematopoietic cell differentiation Nov. 02, 2021
  • Patent Title: Stem cell culture media and methods of enhancing cell survival Oct. 05, 2021
  • Patent Title: Compositions and methods for immune cell modulation in adoptive immunotherapies Aug. 24, 2021
  • Patent Title: Genomic engineering of pluripotent cells Jul. 27, 2021
  • Patent Title: Enhanced stem cell composition Jul. 06, 2021
  • Patent Title: Methods of treating ischemia Apr. 20, 2021
  • Patent Title: Minimal volume reprogramming of mononuclear cells Mar. 23, 2021
  • Patent Title: Methods and compositions for inducing hematopoietic cell differentiation Mar. 16, 2021
  • Patent Title: Enhanced immune effector cells and use thereof Feb. 23, 2021
  • Patent Title: Methods and compositions for inducing hematopoietic cell differentiation Dec. 08, 2020
  • Patent Title: Cell potency assay for therapeutic potential Dec. 01, 2020
  • Patent Title: Cell culture platform for single cell sorting and enhanced reprogramming of ipscs Nov. 24, 2020
  • Patent Title: Genomic engineering of pluripotent cells May. 14, 2019
  • Patent Title: Enhanced stem cell composition Jan. 08, 2019
  • Patent Title: Methods of treating ischemia Oct. 30, 2018
  • Patent Title: Minimal volume reprogramming of mononuclear cells Jul. 17, 2018
  • Patent Title: Stem cell culture media and methods of enhancing cell survival Apr. 17, 2018
  • Patent Title: Wnt compositions and therapeutic uses of such compositions Jan. 23, 2018
  • Patent Title: Cell culture platform for single cell sorting and enhanced reprogramming of ipscs Aug. 15, 2017
  • Patent Title: Enhanced stem cell composition Sep. 27, 2016
  • Patent Title: Wnt compositions and therapeutic uses of such compositions Aug. 02, 2016
  • Patent Title: Small molecule compounds to treat hearing loss Jun. 21, 2016
  • Patent Title: Treatment of muscle disease characterized by insulin resistance Mar. 31, 2015
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard
Government Contracts

Estimated quarterly amount awarded to FATE from public contracts

Quiver Logo

No recent Government Contracts for this ticker

Government Contracts Dashboard
FATE News

Recent insights relating to FATE

CNBC Recommendations

Recent picks made for FATE stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in FATE

FATE Analyst Ratings

FATE Stock Forecasts
...

  • ... Highest Price Target
  • ... Median Price Target
  • ... Lowest Price Target
FATE Analyst Forecasts
Analyst
Firm
Current
Previous
Date
Frequently Asked Questions
  • Is $FATE stock a Buy, Sell, or Hold?

  • What is the price target for $FATE stock?

* Analyst consensus is not financial advice. Please see our data disclaimers .

FATE Top Shareholders
Shareholder
Shares Held
FATE Options Owners
Shareholder
Security
Underlying Shares
Frequently Asked Questions
  • Who owns $FATE stock?

  • Who owns the most shares of $FATE stock?

  • What funds own $FATE stock?

* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.

FATE Stock Smart Score

The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.

The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?

Sign Up to view FATE Smart Score

Score Breakdown
Bull Case vs Bear Case

See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.

Example:

Bulls Say:

The Bulls Say summary highlights positive aspects of the stock.

Bears Say:

The Bears Say summary points out potential risks and negative aspects of the stock.

Show More
About FATE

Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.

  • Address San Diego, CA
  • Market Cap 118.8 million
  • Employees 181
  • Industrial Classification Biological Products, (No Disgnostic Substances)
Back To Top